ACRV Stock Analysis: Buy, Sell, or Hold?
ACRV - Acrivon Therapeutics, Inc. Common Stock
$2.09
0.24 (12.97%)
▲
5d:
+9.42%
30d:
+43.15%
90d:
+16.76%
HOLD
MODERATE Confidence
Analysis Updated: May 1, 2026 12:00 AM ET
Earnings: May 13, 2026
10d
Get Alerted When ACRV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: ACRV is 13.0% above its trading range ($1.85). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: ACRV is 13.0% above its trading range ($1.85). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: ACRV is currently trading at $2.09, which is considered extended relative to its 30-day fair value range of $1.46 to $1.85.
Technical Outlook: Technically, ACRV is in a downtrend. The price is approaching resistance at $2.09. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 13.0% recently.
Market Sentiment: ACRV has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.50 (+450.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ACRV is in a downtrend. The price is approaching resistance at $2.09. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 13.0% recently.
Market Sentiment: ACRV has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.50 (+450.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.46 -
$1.85
Company Quality Score
67/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+13.0% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+13.0%)
- BULLISH: Trading 450.2% below Wall St target ($11.50)
Trading Range Analysis
30-Day Trading Range
$1.46 -
$1.85
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.75
Resistance Level
$2.09
Current Trend
Downtrend
Technical data as of
May 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.12
Wall Street Target
$11.50
(+450.2%)
Share & Embed Analysis
Last updated: May 02, 2026 1:18 PM ET
Data refreshes hourly during market hours. Next update: 2:18 PM
Data refreshes hourly during market hours. Next update: 2:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACRV showing a specific setup today?
Insider Activity (6 Months)
3
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Adam D Levy
BUY
8832 shares
2026-01-14
Peter Blume-Jensen
BUY
49000 shares
2026-01-14
Eric Devroe
BUY
10000 shares
2026-01-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$99 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$93 | 60 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 63 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 52 HOLD |
